Myriad Genetics Corporate Presentation 6/4/13

Size: px
Start display at page:

Download "Myriad Genetics Corporate Presentation 6/4/13"

Transcription

1 Myriad Genetics Corporate Presentation 6/4/13

2 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company s projections or forward-looking statements.

3 Well-Positioned Industry Leader Myriad Genetics is dedicated to saving lives and improving the quality of life of patients through the discovery and commercialization of novel, transformative diagnostic tests across all major diseases Myriad is focused on every aspect of the disease process across the continuum of complete patient care Assessing risk of disease Ensuring rapid & accurate diagnosis Predicting progression Guiding treatment decisions

4 Multiple Growth Opportunities Business Strategy Growing Existing Markets Expanding Global Presence Launching New Products Fuel Strong Long-Term Top Line Growth

5 Broadening Disease Focus Current Markets Future Markets Preventive Care Urology Oncology Oncology Preventive Care Urology Dermatology Autoimmune Neuroscience Developing Tests Across Multiple Diseases

6 Myriad International Network Myriad products are now represented in > 80 countries by 40 distributors MYGN Direct Distribution MYGN Distributor Country

7 The Myriad Vision A TRUSTED ADVISOR ANSWERING PATIENT S MOST PRESSING CONCERNS RISK ASSESSMENT GUIDE THERAPY DIAGNOSIS COMPLETE PATIENT CARE PROGRESSION

8 First Patient Concern; What s My Risk? Identifying hereditary disease saves lives Future of genetic testing is pan-disease panels Myriad s myrisk Hereditary Cancer test will be first comprehensive pan-cancer panel 100% 75% 82% 71% 87% 75% General Population Risk 50% 44% Hereditary Cancer Risk 25% 0% 5% Colorectal Cancer Risk 1% 2% 1% Endometrial Cancer Risk 12% 5% 5% 1% 2% 1% Breast Cancer Risk Ovarian Cancer Risk Melanoma Risk Risk With Preventive Measures

9 Solution: myrisk Hereditary Cancer Product Profile: 25 gene panel (sequencing + large rearrangements) Clinically actionable genes (current genes + others) Initial focus on breast, colon, ovarian, endometrial, pancreatic, and melanoma Future expansion to lung, prostate, all cancers Turn around time 14 days or less List price between $4,000 and $4,500 Projected gross margin of 87%

10 myrisk Hereditary Cancer Market Expansion Eligible Patients Cancer Indications Health Economics Increased sensitivity expands criteria New genes expand cancer indications Comprehensive cancer risk report Improves health economics

11 Expansion Phase: New Indications ONCOLOGY CURRENT: 300,000 per year BREAST 30% COLON 25% OVARIAN 100% FY16: 600,000 per year BREAST 60% COLON 60% OVARIAN 60% ENDO 60% Pancreas 60% Melanoma 60% CANCER SCREEN = 1.6 MILLION PATIENTS

12 Differentiation Phase: Trusted Advisor Competitors Miss 60% of Positives Health Economics MUST KNOW True Positives prevent cancer True Negatives avoid unecessary screening and surgery FOUND MISSED (myrisk) MISSED (BART) MISSED (Database)

13 Solution: myrisk Hereditary Cancer Strategic Objectives: Launch in Fall of 2013 Convert entire hereditary cancer market by summer 2015 and discontinue BRACAnalysis, COLARIS, COLARIS AP, Melaris, and Panexia Proprietary Genes: Current: BRCA1, BRCA2, BART, RAD51C, PALB2, PTEN, MYH, P16 Future: MITF, ELAC2, others

14 Second Patient Concern; Do I Have Disease? Cancer diagnosis today involves considerable judgment Future of cancer diagnosis will use molecular diagnostics for more accurate detection 14% of All Skin Biopsies Are Indeterminate 14% Quicker and more accurate diagnosis like MelaPath saves lives and improves patient healthcare 86%

15 Third Patient Concern; How Aggressive is My Disease? Physicians have difficulty accurately predicting whether or not patient s disease will progress 100% PROLARIS Predicts Prostate Cancer Survival 90% Physicians don t know how aggressively to treat patients and frequently over-treat patients Molecular diagnostic tests like PROLARIS will save lives, improve quality of life, and reduce healthcare costs Prostate Cancer Survival Over 10 Years (%) 75% 50% 25% 0% Low PROLARIS Score 22% High PROLARIS Score

16 PROLARIS Competitive Advantages PROLARIS Indications Biopsy, Prostatectomy Outcome Predicted Patients Studied Gold standard outcomes: Risk of PrCa-specific mortality, metastasis, biochemical recurrence Over 3,000 Published Studies Add l Studies Presented Heterogeneity Sample Requirements accepted 4 Genes show little regional variability Smallest in the industry (20 microns)

17 Queen Mary University of London Study Published in the British Journal of Cancer 100% Study Details N=349 patients Sample type: Biopsy Outcome: Survival Published in the BJC 10-Year Survival 75% 50% 25% 80% 25% 0% Low-Risk PROLARIS Score High-Risk PROLARIS Score

18 PROLARIS Progress To Date Received over 3,000 orders in the last 12 months Significantly better than any other cancer prognostic launch Approximately 90% of current samples are biopsy tissue Received samples from over 350 urologists 24 person sales force PROCEDE data to Medicare by summer 2013 Medicare reimbursement expected in CY14

19 Fourth Patient Concern; What Therapy is Best? Many medicines today are prescribed on a trial and error basis Only about 30% of cancer patients will benefit from any particular chemotherapy Future of drug development is using companion diagnostics to identify responders and non-responders Technology is progressing beyond single-gene biomarkers to focus on disease pathways like Myriad s HRD test Percent of Patients Responding 100% 75% 50% 25% 0% Carboplatin Based Therapy 70% 12% HRD Score > 10 HRD Score < 10

20 Inability to Repair DNA Prevalent in Major Cancers Ovarian tumors (n=747) Esophagus tumors (n=51) Lung tumors (n=226) Brain cell lines (n=19) Prostate tumors (n=23) Colon cell lines (n=42) 490,000 Candidate Patients Per Year = $1B to $2B U.S. Market Opportunity 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% % of Samples With HRD Score > 10

21 Multiple Companion Diagnostic Partnerships Multiple Billion Dollar Markets Pre-IND Phase 1 Phase 2 Phase 3 Post- Marketing Stage Projects Areas Phase II 8 Oncology, Neuropsychiatry Phase III 3 Neuropsychiatry Post-Marketing 3 Neuropsychiatry, Kidney Damage

22 AstraZeneca PARP (Olaparib) Launch: 2015 Olaparib in ovarian cancer: EMA filing in 2013, launch in 2015 EU opportunity for BRCA testing ~30,000 tests/year or $120 million/year Requires BRCA testing with high accuracy & fast turnaround time (< 14days and < 3% VUS rate) Other Solid Tumors Lung Cancer Ovarian Cancer HRD Impaired Cancer Gastric Cancer Advanced Breast Cancer Early TN Breast Cancer Opportunities beyond ovarian cancer Myriad is only Company that can achieve turnaround times and accuracy needed for a companion launch

23 Projected Change in Market Opportunity 2013 Global Market Size = $4.2 Billion 2018 Global Market Size = $12.1 Billion $0.4 $1.8 $0.7 $1.2 $2.0 $0.8 $1.4 $3.0 $5.0 BRACAnalysis COLARIS myrisk Cancer PROLARIS Other HRD MelaPath

24 Historical Financial Performance $600 Revenue Growth $200 Operating Income $500 $400 $300 $200 22% CAGR $150 $100 $50 31% CAGR $100 FY08 FY09 FY10 FY11 FY12 $0 FY08 FY09 FY10 FY11 FY12 PF EPS Quarterly ROIC $1.50 $1.25 $ % CAGR 26.0% 24.0% 22.0% 21.1% 24.0% 23.2% 23.5% $ % $ % $0.25 FY08 FY09 FY10 FY11 FY % 4Q12 1Q13 2Q13 3Q13

25 Fiscal Year 2013 Guidance Range Growth MDx Revenue: $560M - $572M 19-21% CDx Revenue: $25M - $28M 19-27% Total Revenue: $595M - $600M 20-21% Diluted EPS: $ $ %

26 Myriad Core Competencies Content Driven Company: Leader in disease profiling Pioneer in understanding cancer risk: Launch myrisk Hereditary Cancer test this fall First comprehensive pan-cancer panel Innovator in companion diagnostics: Launch HRD test in CY2015 for platinum therapies Will revolutionize cancer treatment Trailblazer in guiding threapy: Over 3,000 PROLARIS test orders year-to-date Expect broad reimbursement coverage within 12 months Most Comprehensive Capabilities: Multiple biomarker tools (DNA, RNA, and protein)

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801) News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Myriad Genetics mychoice HRD Update 06/30/2016

Myriad Genetics mychoice HRD Update 06/30/2016 Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events

More information

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018

Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements

More information

Myriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017

Myriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017 Myriad Genetics Fiscal Third-Quarter 2017 Earnings Call 05/02/2017 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

Myriad Financial Assistance Program (MFAP)

Myriad Financial Assistance Program (MFAP) Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.

More information

Hereditary Cancer Products

Hereditary Cancer Products Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Myriad Genetics Fiscal Second-Quarter 2017 Earnings Call 02/07/2017

Myriad Genetics Fiscal Second-Quarter 2017 Earnings Call 02/07/2017 Myriad Genetics Fiscal Second-Quarter 2017 Earnings Call 02/07/2017 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

Forward Looking Statements

Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance 15M Patient

More information

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Corporate Presentation. June 2017

Corporate Presentation. June 2017 v Corporate Presentation June 2017 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E

More information

(MYGN - $34.67 NASDAQ)

(MYGN - $34.67 NASDAQ) G.research, Inc. One Corporate Center Rye, NY 10580-1422 Tel (914) 921-5075 www.gabelli.com July 21, 2015 Gabelli & Company Myriad Genetics (MYGN - $34.67 NASDAQ) Source: Myriad Genetics Slowly But Surely

More information

Corporate Presentation Fourth Quarter 2017

Corporate Presentation Fourth Quarter 2017 Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

33 rd Annual J.P. Morgan Healthcare Conference. January 2015 33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.

More information

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018 36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section

More information

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET

Clovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3

More information

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic

More information

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008

Bank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008 Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on

More information

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET

Clovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant

More information

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009

J.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009 J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various

More information

Wells Fargo Healthcare Conference September 6, 2018

Wells Fargo Healthcare Conference September 6, 2018 Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are

More information

Molecular Diagnostic Solutions for Urologic Cancer

Molecular Diagnostic Solutions for Urologic Cancer 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This

More information

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018 VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may

More information

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins. WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Genetic Testing: who, what, why?

Genetic Testing: who, what, why? Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018 Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

When the question is genetics, the answer is Invitae Invitae Corporation. All Rights Reserved. 1

When the question is genetics, the answer is Invitae Invitae Corporation. All Rights Reserved. 1 When the question is genetics, the answer is Invitae. L A D E N B U R G T H A L M A N N 2 0 1 8 H E A LT H C A R E C O N F E R E N C E S E A N G E O R G E, C H I E F E X E C U T I V E O F F I C E R 2018

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

Corporate Presentation. August 2016

Corporate Presentation. August 2016 v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

More information

Corporate Presentation. First Quarter 2018

Corporate Presentation. First Quarter 2018 Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within

More information

Corporate Presentation. Second Quarter 2018

Corporate Presentation. Second Quarter 2018 Corporate Presentation Second Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

More information

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017 Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

Guardant Health Investor Presentation. January 2019

Guardant Health Investor Presentation. January 2019 Guardant Health Investor Presentation January 2019 Safe harbor statement This presentation contains forward-looking statements, which are statements related to future events that by their nature address

More information

Diagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015

Diagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015 Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking

More information

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

Lung Cancer Screening

Lung Cancer Screening Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas

More information

Corporate Presentation

Corporate Presentation Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking

More information

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

The 100,000 Genomes Project

The 100,000 Genomes Project The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England

More information

FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors

FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

Presentation to AGM 9 November Deborah Rathjen CEO & Managing Director

Presentation to AGM 9 November Deborah Rathjen CEO & Managing Director Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the

More information

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE

ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY

More information

2018 Bank of America Merrill Lynch Healthcare Conference

2018 Bank of America Merrill Lynch Healthcare Conference CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information

More information

GLOBAL & USA CANCER BIOMARKER MARKET to 2018

GLOBAL & USA CANCER BIOMARKER MARKET to 2018 GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline

More information

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future

More information

Opportunities and Challenges in the Development of Companion Diagnostics

Opportunities and Challenges in the Development of Companion Diagnostics Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

DS-8201 Strategic Collaboration

DS-8201 Strategic Collaboration DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015

Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed

More information

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017

Natus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

January 2017 Investor Presentation. confidently live life with ease

January 2017 Investor Presentation. confidently live life with ease January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could

More information

Pascal Soriot, Head of Strategic Marketing

Pascal Soriot, Head of Strategic Marketing Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage

More information

Oncology Therapeutics Market in India to 2018

Oncology Therapeutics Market in India to 2018 Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research

More information

Genomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.

Genomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved. Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements

More information

Accelerate Your Research with Conversant Bio

Accelerate Your Research with Conversant Bio Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely

More information

CLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014

CLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

Clinical Quality Assurance Measures at Myriad Genetic Laboratories:

Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Clinical Quality Assurance Measures at Myriad Genetic Laboratories: Increasing the Clinical Utility and Cost-Effectiveness of Genetic Testing for Hereditary Cancer Syndromes for Patients, Healthcare Providers

More information

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif

More information

Expanding the boundaries of nutrition Luis Cantarell

Expanding the boundaries of nutrition Luis Cantarell Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m

More information

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options

More information

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information